The panel reviewed evidence from multiple single-dose HPV vaccine studies, including India IARC, Costa Rica, Doris, and Kenshe trials. Observational and randomized data consistently show robust, durable immune responses and high efficacy of single-dose schedules, particularly against HPV 16/18. Immune responses remain stable over a decade, comparable to two- or three-dose regimens. Ongoing studies (Escudo, Primavera, Prisma) aim to confirm long-term protection and expand applicability to new vaccine formulations. Policy discussions highlight programmatic advantages of simplified logistics, reduced costs, and improved coverage critical for cervical cancer elimination goals.